References
- TERIS – University of Washington : http://depts.washington.edu/terisdb/ .
- Hsia JC Er SS Tan CT Estes T Ruoslahti E . Alpha-fetoprotein binding specificity for arachidonate, bilirubin, docosahexaenoate, and palmitate. A spin label study . J. Biol. Chem.255 ( 9 ), 4224 – 4227 ( 1980 ).
- Lakhi N Moretti M . Alpha-fetoprotein: Functions and Clinical Applications . Nova Science Publishes , NY, USA ( 2016 ).
- Terentiev AA Moldogazieva NT Levtsova OV et al. Modeling of three-dimensional structure of human alpha-fetoprotein complexed with diethylstilbestrol: docking and molecular dynamics simulation study . J. Bioinform. Comput. Biol.10 , 1241012 ( 2012 ).
- Hong H Branham WS Ng HW et al. Human sex hormone binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor and a-fetoprotein . Toxicol. Sci.143 ( 2 ), 333 – 348 ( 2015 ).
- Mayer EL . An Oncologist's Perspective on the Clinical use of Teratogenic Products . Dana-Farber Cancer Institute , Boston, MA, USA , 20 ( 2012 ). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM333370.pdf .
- Pak V . The use of alpha-fetoprotein for the delivery of cytotoxic payloads to cancer cells . Ther. Deliv.5 ( 8 ), 885 – 892 ( 2014 ).
- Smrkolj T Gubina B Bizjak J Kumer K Fabjan T Osredkar J . Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer . Adv. Clin. Exp. Med.26 ( 7 ), 1085 – 1090 ( 2017 ).
- Ostrand-Rosenberg S Sinha P Figley C et al. Frontline science: myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice . J. Leukoc. Biol.101 ( 5 ), 1091 – 1101 ( 2017 ).
- Pak VN . Selective targeting of myeloid-derived suppressor cells in cancer patients through AFP-binding receptors . Future Sci. OAFSO321 , 10.4155/fsoa-2018-0029 ( 2018 ) ( Epub ahead of print ).
- Belyaev NN Abdolla N Perfilyeva YV et al. Daunorubicin conjugated with alpha-fetoprotein selectively eliminates myeloid-derived suppressor cells (MDSCs) and inhibits experimental tumor growth . Cancer Immunol. Immunother.67 ( 1 ), 101 – 111 ( 2018 ).
- Pak VN . The use of alpha-fetoprotein for treatment of autoimmune diseases and cancer . Ther. Deliv.9 ( 1 ), 37 – 46 ( 2017 ).
- Kulakov VN Moskaleva EIu Severin ES et al. The distribution of iodine-125 labeled alpha-fetoprotein in the animal organism and its accumulation in the tumor . Vestn. Ross. Akad. Med. Nauk.4 , 11 – 15 ( 2012 ).
- Pak V . US6878688 ( 2005 ). http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=6878688.PN.&OS=PN/6878688&RS=PN/6878688 .
- Pak V . EP 1959978 A4 ( 2015 ). https://patents.google.com/patent/EP1959978A4 .
- Arshad NM In LLA Soh TL et al. Recombinant human alpha fetoprotein synergistically potentiates the anti-cancer effects of 1-S-1-acetoxychavicol acetate when used as a complex against human tumours harbouring AFP-receptors . Oncotarget6 ( 18 ), 16151 – 16167 ( 2015 ).
- Alpha Cancer Technologies Inc . www.alpha-cancer.com/ .
- Dudich IV Semenkova LN Tatulov E et al. WO2015075296 A1 ( 2015 ). www.freepatentsonline.com/y2015/0105325.html .
- Sotnichenko AI Severin SE Posypanova GA et al. Water-soluble 2,3,7,8-tetrachlorodibenzo-p-dioxin complex with human alpha-fetoprotein: properties, toxicity in vivo and antitumor activity in vitro . FEBS Lett.450 ( 1–2 ), 49 – 51 ( 1999 ).
- Pollard LC Murray J Moody M et al. A randomised, double-blind, placebo-controlled trial of a recombinant version of human alpha-fetoprotein (MM-093) in patients with active rheumatoid arthritis . Ann. Rheum. Dis.66 , 687 – 689 ( 2007 ).